Biocon, Voluntis tie up on digital therapeutics

[ad_1]

BENGALURU: Biocon Biologics, a subsidiary of biopharmaceutical company Biocon, has partnered with Voluntis to develop and distribute digital therapeutics for people with diabetes.The licensing agreement, signed by Biocon Biologics’ subsidiary Biocon Sdn Bhd – Malaysia and the France-based digital therapeutics company, would make Biocon Biologics one of the first insulin companies to offer a US Food and Drug Administration-cleared digital therapeutic product – Insulia – for Type 2 diabetes patients across several global markets, Biocon said in a statement.Insulia provides automated insulin dose recommendations and coaching messages for people with diabetes, while enabling the healthcare team to remotely monitor their progress.A healthcare practitioner prescribes Insulia using a dedicated web portal and sets up the treatment plan rules that will adjust basal insulin dosing based on the person’s specific needs.The user then receives an activation code to get started with a personalised app. Once downloaded, the app uses blood glucose readings and any hypo symptoms to recommend doses in real-time.

[ad_2]

Source link
[ad_2]

Share This Post

Share on whatsapp
Share on facebook
Share on twitter
Share on pinterest
Share on reddit
Share on telegram
Share on email
Share on linkedin
Share on print

Posted By :

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

More to Explore

Want to Write Such Blogs?

Just Fill in Your Details to get started

Want to Write such blogs?

Join in like all our authors and be a part of this community

small_c_popup.png

Hello

We are happy you are here

[wppb-login]

Oh No!

It seems like you have forgotten your password. Don’t worry tell us your email id or username and we’ll try to help
Share on whatsapp
Share on twitter
Share on facebook
Share on pinterest
Share on reddit
Share on telegram
Share on email
Share on linkedin
Share on print
error: Alert: Content is protected !!
Secured By miniOrangeSecured By miniOrange